Page URL:

Sure Genomics offers direct-to-consumer whole-genome sequencing

15 February 2016
Appeared in BioNews 839

US start-up company Sure Genomics has launched the first whole-genome testing service available directly to consumers, for a cost of US $2500.

The Utah-based firm will use whole-genome sequencing to create individual reports on characteristics such as drug interactions and responses, fitness, nutrition and ancestry.

The reports will also include information on BRCA1 and BRCA2 gene mutations, which can strongly predispose a person to breast and ovarian cancer.

'Our company is dedicated to making personal DNA information accessible, while providing an engaging platform to help foster deeper understanding of what our DNA says about ourselves,' said Warren Little, CEO and co-founder of Sure Genomics.

'Just one test provides a lifetime of discoveries, helping us make more informed decisions about our personal health – and potentially our future generations.'

Aside from the $2500 test fee, there is also a $150 annual subscription fee, which customers must pay to receive twice-yearly re-analysis of their genetic data.

In contrast to their competitors 23andMe and Ancestry, the company says it will not sell or share personal information about its customers.

However, from a regulatory standpoint, there is much ambiguity regarding whether Sure Genomics should be providing information on BRCA1 and BRCA2 since the Food & Drug Administration (FDA) has not cleared direct-to-consumer tests for these mutations.

The FDA previously came down heavily on 23andMe for its direct-to-consumer genetic health tests (see BioNews 733), and Anne Wojcicki's company is still only allowed to provide limited information on disease risk to customers in the US (see BioNews 825). It appears as if, initially, Sure will only be providing disease-risk information on BRCA1 and BRCA2 and states it intends to 'release additional reports after they meet all required FDA  regulatory standards'.

'We have been in contact with the FDA and we feel like we've built a system and process that would meet their requirements,' said Sure Genomics co-founder Rick White. '[Our] reports are going to be delivered in, I would say, an ultra-compliant manner,' he added.

The company also seems to be appeasing the FDA by having an in-house physician to prescribe the genetic testing. Those who make use of the service can also have a one-hour consultation with a genetic counsellor, although this is optional.

But Professor Mark Rothstein, from the University of Louisville, said he didn't believe the use of a prescribing doctor would influence the FDA. 'I don't think getting a doctor to order the test changes anything,' he told The Verge.

The FDA has previously expressed misgivings over direct-to-consumer genetic testing because of risks such as false-positives and -negatives, and concerns the results may lead patients to make decisions that adversely affect their health.

For $2,500 this company will lay out your entire genetic blueprint
Business Insider |  9 February 2016
Sure Genomics Aims to Offer Whole-Genome Sequencing to Consumers
Genomeweb |  11 November 2015
Sure Genomics Introduces First Full DNA Sequence to Consumers Delivered on an Interactive, Easy to Comprehend Platform
BusinessWire (press release) |  9 February 2016
Sure Genomics wants to sell private genetic profiles for $2,500, but it’s really testing the FDA
The Verge |  9 February 2016
The Whole Thing
Genomeweb |  10 February 2016
3 July 2017 - by Cara Foley 
Approximately 22 percent of healthy adults carry mutations that are associated with disease, found the first ever randomised clinical trial using whole-genome sequencing...
23 January 2017 - by Kulraj Singh Bhangra 
Scientists have created a smartphone microscope attachment that can image and analyse DNA sequences...
18 April 2016 - by Elie Diner 
Scientists searching through nearly 600,000 genome sequences have found 13 'superhumans' who are symptom-free despite carrying mutations for severe childhood diseases...
21 March 2016 - by Ryan Ross 
A recent study has suggested that genetic tests to assess the risk of diseases like diabetes and lung cancer do little to motivate people to change their behaviour...
21 March 2016 - by Dr Helen Robertson 
'Personalised medicine' is a term that's being increasingly used to describe the future of cancer treatment. But are we ready for the genomics revolution that comes with it?...
25 January 2016 - by Rikita Patel 
The US National Institutes of Health (NIH) has pledged over US$280 million over the next four years to genome sequencing targeting common and rare human diseases...
14 December 2015 - by Andelka M. Phillips 
There is now a huge range of direct-to-consumer genetic tests on the market, but the public ought to be wary of what exactly they are agreeing to when they sign up for these services...
16 November 2015 - by Lone Hørlyck 
The US Food and Drug Administration has sent warning letters to three gene-testing companies over the marketing and selling of what it claims are direct-to-consumer gene testing products without its approval...
22 October 2015 - by Julianna Photopoulos 
Genetic testing company 23andMe is relaunching its direct-to-consumer genetic tests in the USA, after receiving approval from the US Food and Drug Administration...
2 March 2015 - by Alice Hazelton 
Genome sequencing offers great potential for the effective diagnosis and future treatment of many conditions. But while the excitement continues to grow around the science, few have stopped to ask what patients, the ultimate end-beneficiaries of this technology, think...
to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions

Syndicate this story - click here to enquire about using this story.